Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Approval symbols : Tak save search
Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
Published: 2024-03-26 (Crawled : 18:00) - biospace.com/
TAK | $13.18 -1.42% -0.3% 1.8M
|
Health Technology
|
| O: 1.84%
H: 0.24%
C: -0.14%
adzynma japan takeda approval injection
Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL
Published: 2024-03-19 (Crawled : 17:00) - biospace.com/
TAK | $13.18 -1.42% -0.3% 1.8M
|
Health Technology
|
| O: -0.07%
H: 0.0%
C: -0.96%
iclusig fda drug takeda approval application
Takeda Announces China NMPA Approval of LIVTENCITY® (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Refractory to Prior Therapies
Published: 2023-12-21 (Crawled : 00:00) - biospace.com/
TAK | $13.18 -1.42% -0.3% 1.8M
|
Health Technology
|
| O: 2.05%
H: 0.29%
C: 0.0%
livtencity approval cytomegalovirus treatment china
Takeda Announces Approval of CUVITRU™ Subcutaneous Immunoglobulin in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia
Published: 2023-09-25 (Crawled : 15:00) - biospace.com/
TAK | $13.18 -1.42% -0.3% 1.8M
|
Health Technology
|
| O: 0.57%
H: 0.38%
C: 0.25%
japan approval
Global Hemophilia Research Analysis Report 2023: A $21.07 Billion Market by 2030 - Approval of Gene Therapies and Monoclonal Antibodies Fueling Growth
Published: 2023-08-16 (Crawled : 01:00) - prnewswire.com
TAK | $13.18 -1.42% -0.3% 1.8M
|
Health Technology
|
| O: -0.26%
H: 0.26%
C: -0.46%
PFE A | $25.91 0.19% -0.19% 28M
|
Health Technology
|
| O: -0.71%
H: 1.45%
C: 0.97%
NVO | $123.9 -0.49% -0.47% 2.8M
|
Health Technology
|
| O: -0.3%
H: 1.35%
C: 0.05%
SNY | $46.24 0.68% 0.63% 1.6M
|
Health Technology
|
| O: -1.33%
H: 0.0%
C: 0.0%
report approval research global growth market
Takeda Receives FDA Approval to Expand the Use of HYQVIA® to Treat Primary Immunodeficiency in Children
Published: 2023-04-11 (Crawled : 13:20) - biospace.com/
TAK | $13.18 -1.42% -0.3% 1.8M
|
Health Technology
|
| O: -0.36%
H: 0.35%
C: -0.12%
hyqvia fda children approval
Takeda’s EXKIVITY® (mobocertinib) Receives Approval from the NMPA of China, Becoming the First and Only Therapy Available for Patients with EGFR Exon20 Insertion+ NSCLC
Published: 2023-01-11 (Crawled : 14:00) - biospace.com/
TAK | $13.18 -1.42% -0.3% 1.8M
|
Health Technology
|
| O: 1.04%
H: 0.32%
C: 0.19%
exkivity approval therapy
Takeda Receives Positive CHMP Opinion Recommending Approval of Dengue Vaccine Candidate in EU and Dengue-Endemic Countries
Published: 2022-10-14 (Crawled : 15:00) - biospace.com/
TAK | $13.18 -1.42% -0.3% 1.8M
|
Health Technology
|
| O: 0.62%
H: 0.69%
C: -0.69%
candidate chmp vaccine dengue approval positive tak-003 qdengue
Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Published: 2022-05-03 (Crawled : 18:00) - biospace.com/
TAK | $13.18 -1.42% -0.3% 1.8M
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: 0.0%
BMY | $48.51 0.48% 0.19% 9.8M
|
Health Technology
|
| O: 0.36%
H: 0.0%
C: 0.0%
EXEL 4 | $22.7 -0.48% -0.51% 1.8M
|
Health Technology
|
| O: 0.09%
H: 1.54%
C: -0.44%
cabometyx approval cancer
Takeda Announces Approval of Nuvaxovid® COVID-19 Vaccine for Primary and Booster Immunization in Japan
Published: 2022-04-19 (Crawled : 06:00) - biospace.com/
TAK | $13.18 -1.42% -0.3% 1.8M
|
Health Technology
|
| O: -2.23%
H: 0.0%
C: 0.0%
covid-19 nuvaxovid vaccine approval
Novavax Announces Submission of New Drug Application in Japan for Approval of COVID-19 Vaccine
Published: 2021-12-16 (Crawled : 05:00) - prnewswire.com
TAK | $13.18 -1.42% -0.3% 1.8M
|
Health Technology
|
| O: 1.18%
H: 0.0%
C: 0.0%
NVAX | $4.12 -3.74% -3.63% 4.7M
|
Health Technology
|
| O: 5.55%
H: 0.0%
C: 0.0%
covid-19 new drug application drug approval covid vaccine submission
Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 3b Study for ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern
Published: 2021-10-12 (Crawled : 13:00) - biospace.com/
TAK | $13.18 -1.42% -0.3% 1.8M
|
Health Technology
|
| O: 0.21%
H: 0.14%
C: -1.05%
JNJ | $147.59 0.05% -0.18% 6.4M
|
Health Technology
|
| O: -0.16%
H: 0.11%
C: -1.44%
ARCT 4 | $29.31 -3.68% -3.82% 610K
|
Health Technology
|
| O: 4.89%
H: 1.6%
C: -1.84%
vaccine phase 3 approval sars-cov-2
Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 2 and Phase 3a for ARCT-154, Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern
Published: 2021-09-22 (Crawled : 12:00) - biospace.com/
TAK | $13.18 -1.42% -0.3% 1.8M
|
Health Technology
|
| O: -0.17%
H: 0.0%
C: -1.11%
JNJ | $147.59 0.05% -0.18% 6.4M
|
Health Technology
|
| O: 0.5%
H: 0.36%
C: -0.86%
ARCT 4 | $29.31 -3.68% -3.82% 610K
|
Health Technology
|
| O: 1.81%
H: 2.1%
C: -0.32%
phase 2 vaccine phase 3 approval sars-cov-2
Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Published: 2021-09-17 (Crawled : 22:00) - biospace.com/
TAK | $13.18 -1.42% -0.3% 1.8M
|
Health Technology
|
| O: -0.06%
H: 0.0%
C: 0.0%
EXEL 4 | $22.7 -0.48% -0.51% 1.8M
|
Health Technology
|
| O: -0.61%
H: 0.0%
C: 0.0%
fda fda approval cancer approval
Exelixis Announces Partner Takeda and Ono Receive Approval in Japan for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) for the Treatment of Unresectable or Metastatic Renal Cell Carcinoma
Published: 2021-08-25 (Crawled : 22:00) - biospace.com/
TAK | $13.18 -1.42% -0.3% 1.8M
|
Health Technology
|
| O: -0.24%
H: 0.27%
C: 0.0%
BMY | $48.51 0.48% 0.19% 9.8M
|
Health Technology
|
| O: -0.38%
H: 0.07%
C: -0.97%
EXEL 4 | $22.7 -0.48% -0.51% 1.8M
|
Health Technology
|
| O: -0.37%
H: 2.23%
C: 0.27%
treatment renal approval cell carcinoma nivolumab
Arcturus Announces Approval of Singapore Clinical Trial Application to Advance ARCT-154 and ARCT-165, Next Generation STARR™ mRNA Vaccines Targeting SARS-CoV-2 Variants of Concern, in a Phase 1/2 Study
Published: 2021-08-03 (Crawled : 12:00) - biospace.com/
TAK | $13.18 -1.42% -0.3% 1.8M
|
Health Technology
|
| O: -0.06%
H: 0.0%
C: -0.6%
JNJ | $147.59 0.05% -0.18% 6.4M
|
Health Technology
|
| O: 0.27%
H: 1.02%
C: 0.96%
ARCT 4 | $29.31 -3.68% -3.82% 610K
|
Health Technology
|
| O: 13.79%
H: 51.6%
C: 47.69%
phase 1 vaccine trial approval sars-cov-2
Arcturus Announces Approval of a Clinical Trial Application to Advance ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting the SARS-CoV-2 Delta Variant and Other Variants of Concern
Published: 2021-08-02 (Crawled : 14:00) - biospace.com/
TAK | $13.18 -1.42% -0.3% 1.8M
|
Health Technology
|
| O: -0.36%
H: 0.75%
C: -0.18%
JNJ | $147.59 0.05% -0.18% 6.4M
|
Health Technology
|
| O: 0.02%
H: 0.21%
C: -0.12%
ARCT 4 | $29.31 -3.68% -3.82% 610K
|
Health Technology
|
| O: 6.36%
H: 9.92%
C: 5.16%
vaccine trial approval sars-cov-2
Arcturus Announces Regulatory Approval to Proceed with Phase 2 Study of ARCT-810 mRNA Therapeutic Candidate for Ornithine Transcarbamylase (OTC) Deficiency
Published: 2021-07-28 (Crawled : 15:00) - biospace.com/
TAK | $13.18 -1.42% -0.3% 1.8M
|
Health Technology
|
| O: 0.42%
H: 2.14%
C: 1.72%
JNJ | $147.59 0.05% -0.18% 6.4M
|
Health Technology
|
| O: 0.04%
H: 0.38%
C: -0.32%
ARCT 4 | $29.31 -3.68% -3.82% 610K
|
Health Technology
|
| O: -0.19%
H: 6.93%
C: 6.54%
phase 2 approval
Takeda Announces Approval of Moderna’s COVID-19 Vaccine in Japan
Published: 2021-05-21 (Crawled : 09:00) - biospace.com/
TAK | $13.18 -1.42% -0.3% 1.8M
|
Health Technology
|
| O: 0.75%
H: 0.63%
C: -0.17%
JNJ | $147.59 0.05% -0.18% 6.4M
|
Health Technology
|
| O: 0.15%
H: 0.82%
C: -0.22%
covid vaccine approval covid-19
Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cabometyx® (cabozantinib) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma
Published: 2021-04-14 (Crawled : 00:00) - biospace.com/
TAK | $13.18 -1.42% -0.3% 1.8M
|
Health Technology
|
| O: 0.0%
H: 1.09%
C: 0.35%
BMY | $48.51 0.48% 0.19% 9.8M
|
Health Technology
|
| O: 0.27%
H: 0.33%
C: 0.09%
EXEL 4 | $22.7 -0.48% -0.51% 1.8M
|
Health Technology
|
| O: -0.38%
H: 4.2%
C: 3.09%
treatment europe renal approval cell carcinoma nivolumab
Gainers vs Losers
| 45% | 55% |
Top 10 Gainers
KAVL | $6.3 135.96% 57.45% 44M
|
Wholesale Trade
PXMD | $0.74 79.7% 44.16% 4.5M
|
Health Technology
DYNT | $0.3704 -5.27% 43.09% 5.5M
|
Health Technology
LGVN P 3 d | $2.93 73.37% 42.52% 56M
|
HUBC | $1.95 50.0% 32.99% 73M
|
n/a
SPCB | $0.4004 45.07% 31.75% 130M
|
Electronic Technology
ONVO | $1.35 33.65% 24.62% 53M
|
Health Technology
OMQS | $0.7038 35.35% 24.3% 3.5M
|
Professional, Scientific, and T...
SNPO | $10.54 29.48% 22.88% 3.9M
|
MDJH | $1.59 23.26% 19.88% 14K
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.